Effect of Abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes - Observations from the TARGET trial

American Journal of Cardiology

Volumn 92, Issue 2, 2003, Pages 125-129

  Casserly, Ivan P ^b   Topol, Eric J ^b   Jia, Gang ^b   Lange, Richard A ^b   Hamm, Christian ^b   Meier, Bernhard ^b   DiBattiste, Peter M ^b   Lakkis, Nasser ^b   Chew, Derek P ^b   Stone, Gregg W ^b   Cohen, David J ^b   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MONOCLONAL ANTIBODY; TIROFIBAN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0038306398     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00525-3     Document Type: Article

References (22)

1. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet. 353:1999;227-231.
2. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol E.J. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol. 75:1995;559-562.
3. Ambrose J.A., Hawkey M., Badimon J.J., Coppola J., Geagea J., Rentrop K.P., Domiguez A., Duvvuri S., Elmquist T., Arias J., Doss R., Dangas G. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol. 86:2000;150-152.
4. Ammar T., Scudder L.E., Coller B.S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 95:1997;614-617.
5. Herault J.P., Peyrou V., Savi P., Bernat A., Herbert J.M. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost. 79:1998;383-388.
6. Keularts I.M., Beguin S., de Zwaan C., Hemker H.C. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost. 80:1998;370-371.
7. Pedicord D.L., Thomas B.E., Mousa S.A., Dicker I.B. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 90:1998;247-258.
8. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 98:1996;863-874.
9. Byzova T.V., Plow E.F. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol. 143:1998;2081-2092.
10. Altieri D.C., Edgington T.S. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem. 263:1988;7007-7015.
11. Altieri D.C., Morrissey J.H., Edgington T.S. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation an alternative initiation of the coagulation protease cascade . Proc Natl Acad Sci USA. 85:1988;7462-7466.
12. Furman M.I., Krueger L.A., Frelinger A.L. III, Barnard M.R., Mascelli M.A., Nakada M.T., Michelson A.D. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 84:2000;492-498.
13. Dangas G., Marmur J.D., King T.E., De Leon J., Sharma S.K., Vidhun R., Feldman D., Stoynov M.Y., Badimon J.J., Ambrose J.A. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J. 138:1999;49-54.
14. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., DiBattiste P.M., Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894.
15. Bowers J., Ferguson J.J. III. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol. 17:1994;357-361.
16. Moliterno D.J., Topol E.J. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement rationale and design of the TARGET study . Am Heart J. 140:2000;722-726.
17. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 320:1989;618-627.
18. Gemmell C.H., Sefton M.V., Yeo E.L. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem. 268:1993;14586-14589.
19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
20. Ambrose J.A., Doss R., Geagea J.M., Hawkey M.C., Duvuri S., Giedd K., Dominguez A., Coppola J., Nguyen T.H., Palla V., Barua R.S., Saha D.C. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention. Am J Cardiol. 87:2001;1231-1233.
21. Dauerman H.L., Ball S.A., Goldberg R.J., Desourdy M.A., Furman M.I. Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. J Thromb Thrombolysis. 13:2002;127-132.
22. Roffi M., Moliterno D.J., Meier B., Powers E.R., Grines C.L., DiBattiste P.M., Herrmann H.C., Bertrand M., Harris K.E., Demopoulos L.A., Topol E.J. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up . Circulation. 105:2002;2730-2736.